WALTHAM, Mass.–(BUSINESS WIRE)–November 17, 2016–
Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. John Pedersen, Chief Executive Officer is scheduled to present at 1:10 p.m. Eastern Time.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.
Eileen Gardner, RN, 781-902-1625
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more